 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

We have seen breakout of consolidation range in Poly Medicure, which has formed long bullish candlestick pattern on the daily scale with above average volumes. The stock ended at fresh record closing high of Rs 1,222, rising 6.7 percent.

Trade Spotlight | Your trading strategy for Syngene International, Poly Medicure, Raymond today

Syngene Intl Consolidated June 2023 Net Sales at Rs 808.10 crore, up 25.38% Y-o-Y

The manufacturing unit has a potential for future expansion up to a further 20,000 litres of biologics drug substance manufacturing capacity.

Strides Pharma sinks after subsidiary plans to divest manufacturing plant

The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday.

Syngene to acquire plant from Stelis Biopharma for Rs 702 crore

ICICI Direct is bullish on Syngene International recommended buy rating on the stock with a target price of Rs 740 in its research report dated April 27, 2023.

Buy Syngene International; target of Rs 740: ICICI Direct

Syngene Intl Consolidated March 2023 Net Sales at Rs 994.40 crore, up 31.17% Y-o-Y

Syngene Intl Standalone March 2023 Net Sales at Rs 994.40 crore, up 31.07% Y-o-Y

Market participants expect the trend of block deals to intensify given the uncertain macro-economic outlook both at the global and domestic level 

Supply of shares on the rise as large investors, promoters lower their stakes 

As of December end, Biocon held 64.5 percent promoter stake in Syngene International. After the block deal, this will go down to 54.5 percent.

Syngene International sees 4 crore shares sold in block deal, Biocon likely seller

The offer price band ranges around Rs 560 to Rs 562.30 per share. The company is likely to raise Rs 2,240 crore at lower end via the deal.

Biocon likely to sell 10% equity stake in Syngene on Feb 1 via block deal

Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. It is engaged providing contract research and manufacturing services. The firm’s services include discovery chemistry, discovery biology, safety assessment, large molecule development, chemical development, formulation development, stability studies, polymer research, integrated discovery and development, and clinical development. The company was founded on November 18, 1993 and is headquartered in Bangalore, India.

Watchers	90
52-Wk Low	534.57
52-Wk High	860.25

Market Cap	311.31B
Volume (M)	987,618.00
52-Wk High	860.25
52-Wk Low	534.57

Current Price	777.95
Prev Close	770.05
Open	776.45
Dividend Yield	0.08%
50-Day Moving Average	799.27
Beta	0.02
Avg. Volume	605,434.09
PE Ratio	64.49

52-Week High	860.25
52-Week Low	534.57
Market Capitalization	311.31B
EPS	12.06
Price to Book	8.10
Revenue Per Employee	4.9M
Enterprise Value/EBITDA	29.27

SYNGENE.NSE Syngene International Ltd.

About

Feed

News

Sentiment

Fundamentals